Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02393118
Other study ID # WCB14-492
Secondary ID CDMRP-DM130076
Status Active, not recruiting
Phase N/A
First received March 2, 2015
Last updated March 1, 2016
Start date September 2014
Est. completion date September 2016

Study information

Verified date March 2016
Source Wicab
Contact n/a
Is FDA regulated No
Health authority United States: Federal GovernmentUnited States: Food and Drug AdministrationUnited States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The BrainPort V200 Device is a wearable, non-surgical, prosthetic device intended for people who are profoundly blind. The BrainPort V200 translates images captured by a digital camera into electro-tactile stimulation presented on the user's tongue to perceive shape, size, location, and motion of objects within the environment. The purpose of this study is to evaluate the safety and functional performance of the BrainPort V200 device in individuals who have been medically documented as blind, light perception or worse, due to a traumatic injury (cortical or ocular).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 20
Est. completion date September 2016
Est. primary completion date September 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. A minimum age of 18 years at enrollment.

2. A documented vision diagnosis of light perception or worse bilaterally.

3. Blinded by traumatic injury (i.e., ocular or cortical trauma).

4. Minimum post 12 months diagnosis of blindness.

5. Previous completion of conventional rehabilitation such as orientation and mobility training with a cane or guide dog.

6. Ability to read (or have read to them) and understand study documents and procedures.

7. Ability to provide valid feedback regarding use of the BrainPort device.

8. Access to an accessible computer and internet connection.

9. Willing and able to complete all questionnaires, telephone conferences, device training, and study procedures required by the protocol, after completing an orientation period with the device.

10. Ability to operate a tablet computer.

Exclusion Criteria:

1. Current oral health problems determined by the participant's medical history and an examination of the oral cavity performed by study personnel.

2. History of injury to the tongue resulting in impaired sensation of use of the tongue.

3. Visible open lesions, cold sores, abrasions, blisters, or rash on the tongue, numbness or lack of feeling of the tongue.

4. Piercings on the tongue.

5. Recent or planned oral surgery and/or dental work in the past three months (does not include routine dental health exams/cleanings).

6. Known neuropathies of the tongue or tactile system.

7. History of seizures or epilepsy.

8. If female, pregnant or breast feeding by self-report. Women of child bearing potential must agree to use appropriate birth control to prevent pregnancy for the duration of the study.

9. People with implanted medical devices (i.e., pacemaker, deep brain stimulator, cochlear implant).

10. Any hearing impairments which prevents hearing the device announcements.

11. Any cognitive disabilities (such as Alzheimer's disease), as determined by medical history and/or the Telephone Inventory Cognitive Screening (TICS).

12. Participation in any other clinical trial or research while my confound results in either study.

13. Known allergy to nickel, gold, or any component of stainless steel.

14. Any medical condition that would interfere with performance on the assessments.

15. The Site Principal Investigator does not deem the candidate to be suitable for the study for other reasons not listed above.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care


Related Conditions & MeSH terms


Intervention

Device:
BrainPort V200 Device
Training in clinic on use of the device for 2-3 days (10 hours) followed by in-home use for a minimum of 300 minutes per month over 12 months.

Locations

Country Name City State
United States The Chicago Lighthouse for People Who Are Blind or Visually Impaired Chicago Illinois
United States Wicab, Inc. Middleton Wisconsin
United States Lighthouse Guild New York New York

Sponsors (3)

Lead Sponsor Collaborator
Wicab Lighthouse Guild, The Chicago Lighthouse for People Who Are Blind or Visually Impaired

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Text identification task Words or sequence of numbers will be presented on flashcards and a mobile tablet, subjects will be asked to verbally identify which word or number is presented. 12 months No
Other Navigation task Subjects will be required to identify key characteristics of a room, such as the number of windows and doorways and complete navigation tasks such as following a line, avoiding obstacles, and walking through a doorway without touching any walls. 12 months No
Other Change in the effect of assistive technology on perceived quality of life after using the device for one year as measured by the Psychosocial Impact of Assistive Devices Scale (PIADS). Baseline, 12 months after device training. No
Other Change in self-efficacy after using the device for one year as measured by the General Self-Efficacy Scale (GSES) Basline, 12 months after device training. No
Other Change in perceived general pain after using the device for one year as measured by the Universal Pain Assessment Tool Baseline,12 months after device training No
Other Change in satisfaction of the device after using the device for one year, as measured by the Device Satisfaction Survey One month after start of home use, 12 months after device training No
Other Optional focus group to assess year long experience with the device. 12 months after device training No
Primary To assess the safety of electrical stimulation on the tongue (to demonstrate no occurrence of a clinically significant device-related adverse event) The primary safety objective is to demonstrate no occurrence of a clinically significant device-related adverse event. 12 months Yes
Primary To assess the efficacy of the BrainPort device as measured by an object recognition task (to demonstrate at least 35% of subjects achieve a success rate in object recognition exceeding that expected by chance alone) The primary efficacy objective is to demonstrate that at least 35% of subjects achieve a success rate in object recognition exceeding that expected by chance alone. 12 months No
See also
  Status Clinical Trial Phase
Terminated NCT00262509 - Emergency Egress and Information System for Persons With Vision Loss N/A
Terminated NCT00691444 - Blind Child Melatonin Treatment Study N/A
Recruiting NCT06237829 - Testing Tactile Aids With Blind Subjects N/A
Completed NCT00829036 - Wayfinding Information Access System for People With Vision Loss N/A
Completed NCT01488786 - A Study to Evaluate the BrainPort® Vision Device in Subjects Who Are Blind N/A
Completed NCT02643238 - Continued Study of Artificial Vision: Evaluation of the BrainPort® System and Investigation of Visual Ambulation N/A
Recruiting NCT00403143 - Do Blue-Blocking Lenses Block Blue Colour From Our Lives? N/A
Recruiting NCT06451172 - Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis Early Phase 1
Recruiting NCT04725760 - Evaluation of the Efficacy of the BrainPort Vision Pro on the Performance of Daily Activities in the Profoundly Blind French Population N/A
Recruiting NCT02983370 - Development of a Cortical Visual Neuroprosthesis for the Blind N/A
Not yet recruiting NCT06070467 - Holistic Mixed Approaches to Capture the Real Life of Children With Rare Eye Diseases
Completed NCT01109576 - Workshops for Veterans With Vision and Hearing Loss Phase 0
Completed NCT00920231 - Computer Vision System for the Blind Veteran Phase 1
Terminated NCT00795236 - Melatonin Studies of Totally Blind Children N/A
Terminated NCT00634972 - Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity Phase 4
Enrolling by invitation NCT06364605 - MySpace: the Role of Vision in Representing Space N/A
Terminated NCT03913130 - Extension Study to Study PQ-110-001 (NCT03140969) Phase 1/Phase 2
Not yet recruiting NCT05806684 - Hyperbilirubinemia and Retinopathy of Prematurity in Preterm Infants: a Retrospective Study.
Completed NCT03753893 - Ocular Manifestations in Rheumatic Diseases
Recruiting NCT04855045 - An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene. Phase 2/Phase 3